Cherry Mohamad A

Associate Professor


Dr. Cherry is an associate Professor of Medicine at the University of Oklahoma Health Sciences Center. He is currently the fellowship program director and the lead investigator in the phase I malignant hematology program. He is also the Co-Chair of the leukemia working group at the Sara Canon Research Institute. Dr. Cherry earned his medical degree from the Lebanese University and completed his residency at Staten Island University Hospital, N.Y., and at the American University of Beirut Medical Center, Lebanon. He served as chief hematology-oncology fellow with the OU College of Medicine where he earned his hematology/oncology fellowship. Dr. Cherry has many research interests and has focused through his career on investigating novel therapies for patients with relapsed and refractory leukemia and lymphoma. He is the principal investigator on NCI and pharma-sponsored phase I/II/III clinical trials for patients with leukemia, lymphoma and myeloproliferative neoplasms.


Area of Interest

1) Novel therapies for patients with relapsed and refractory leukemia and lymphoma
2) NCI and pharma-sponsored phase I/II/III clinical trials for patients with leukemia, lymphoma and myeloproliferative neoplasms.

top publication

1) Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - single center experience. Masarova L, Cherry M, Newberry KJ, Estrov Z, Cortes JE, Kantarjian HM, Verstovsek S. Leuk Lymphoma. 2015 Apr 22:1-10. [Epub ahead of print]

2) Role of topotecan, vinorelbine, thiotepa and gemcitabine chemotherapy in relapsed/refractory adult acute leukemia. Srour SA1, Borders EB, Cherry MA, Holter J, Herman T, Selby GB. Leuk Lymphoma. 2015 Mar 31:1-3.

3) A Case of Acute Myeloid Leukemia with a Previously Unreported Translocation (14; 15) (q32; q13). Khawandanah M, Gehrs B, Li S, Holter Chakrabarty J, Cherry M. Case Rep Genet. 2014; 2014:921240. doi: 10.1155/2014/921240

4) Epub 2014 Nov 11. Erlotinib is not effective in patients with JAK2V617F-positive polycythemia vera. Cherry M1, Khawandanah M, Zhao ZJ, Srour S, Ozer H, Selby G, Ghabache B, Al-Kali A. Ann Hematol. 2014 Nov 9. [Epub ahead of print]

5) Autoimmune hemolytic anemia and thrombocytopenia attributed to an intrauterine contraceptive device. Khawandanah MO, Weiss SM, Cherry MA, Maymani H, Selby GB, Aster RH, George JN, Holter Chakrabarty JL. Transfusion. 2014 Sep 11.

6) Catheter-related complications in patients with acute myeloid leukemia after hematopoietic stem cell transplant. Khalil MO, Pierson N, Selby GB, Cherry M, Holter JL. J Vasc Access. 2014 Sep 2;0(0)

7) Outcome of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome According to Health Insurance Status. Al-Ameri A, Anand A, Abdelfatah M, Kanaan Z, Hammonds T, Haller N, Cherry M. Clin Lymphoma Myeloma Leuk. 2014 Jun 12: S2152-2650(14)00137-2
8) An unusual presentation of an aggressive spindle cell skin cancer. Srour SA, Workman M, Yang JT, Abdullah SA, Cherry MA. J Community Support Oncol. 2014 Apr;12(4):149-52.

9) Refractory Classical Hodgkin Lymphoma Presenting with Atypical Cutaneous Involvement and Diagnosis of ZZ Phenotype Alpha-1 Antitrypsin Deficiency. Khawandanah M, Kraus T, Cherry M. Case Rep Hematol. 2014;2014:642868.

10) Central venous catheter-related complications in acute myeloid leukemia patients. Khalil MO, Pierson N, Maymani H, Holter J, Cherry M. J Vasc Access. 2014 Apr 5;0(0):0. doi: 10.5301/jva.5000216.

11) Antitumor activity of an enzyme prodrug therapy targeted to the breast tumor vasculature. Van Rite BD, Krais JJ, Cherry M, Sikavitsas VI, Kurkjian C, Harrison RG. Cancer Invest. 2013 Oct; 31(8):505-10.

12) Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcome. Cherry M, Cardenas-Turanzas M, Pham H, Kantarjian H, Cortes J, Pierce S, Zhou L, Verstovsek S. Leuk Res. 2013 Nov; 37(11):1472-6. Bone Marrow Fibrosis Reversal After Use